| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Prognostic Impact of Adjuvant Immunotherapy in Patients with High-Risk Upper Tract Urothelial Cancer: Results from the ROBUUST 2.0 Collaborative Group. |
| 掲載誌名 | 正式名：Cancers 略 称：Cancers (Basel) ISSNコード：20726694/20726694 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 17(13),pp.2144 |
| 著者・共著者 | Maxwell Otiato, Farshad Sheybaee Moghaddam, Alireza Ghoreifi, Riccardo Autorino, Gabriele Bignante, Chandru Sundaram, Daniel Sidhom, Ithaar H Derweesh, Dhruv Puri, Vitaly Margulis, Benjamin Popokh, Firas Abdollah, Alex Stephens, Matteo Ferro, Giuseppe Simone, Gabriele Tuderti, Reza Mehrazin, Ahmed Eraky, Mark Gonzalgo, Omar Falik Nativ, Zhenjie Wu, Francesco Porpiglia, Enrico N Checcucci, Andres Correa, Randall Lee, Alessandro Antonelli, Alessandro Veccia, Soroush Rais-Bahrami, Alireza Dehghanmanshadi, Nirmish Singla, Stephan Brönimann, Sisto Perdonà, Roberto Contieri, Takashi Yoshida, James Porter, Saum Ghodoussipour, Luca Lambertini, Andrea Minervini, Hooman Djaladat |
| 発行年月 | 2025/06 |
| 概要 | Background/Objective: The impact of adjuvant immunotherapy (IO) on the prognosis of patients with upper tract urothelial carcinoma (UTUC) remains unclear. This study examines the association of adjuvant IO with oncologic outcomes in patients with high-risk UTUC. Methods: This retrospective study reviewed patients with high-risk UTUC treated with adjuvant IO using the ROBotic surgery for Upper tract Urothelial cancer STudy (ROBUUST) database. Propensity-score-matched analysis (nearest-neighbor algorithm, caliper 0.1) was conducted to compare patients receiving adjuvant IO versus those who did not, with matching based on pathologic T and N category and receipt of neoadjuvant chemotherapy. Associations between adjuvant IO and urothelial recurrence-free survival (URFS), non-urothelial recurrence-free survival (NRFS), and overall survival (OS) were estimated using a Cox proportional hazards model. Results: Seventy-five patients received adjuvant IO following nephroureterectomy (median four cycles, including eleven (14.7%) nivolumab, thirty-one (41.3%) pembrolizumab, four (5.3%) atezolizumab, and twenty-nine (38.6%) other agents. These patients were matched to 68 patients without adjuvant therapy. Median follow-up times were 17 (IQR, 10-29) months and 20 (9-44) months for IO and no adjuvant therapy, respectively. Multivariable analysis revealed that adjuvant IO was not associated with URFS, NRFS, or OS. Pathologic nodal involvement (HR 7.52, p < 0.001) was the only independent predictor of worse OS. Conclusions: In this real-world retrospective data set, adjuvant IO does not have an impact on oncologic outcomes of UTUC patients following extirpative surgery. |
| DOI | 10.3390/cancers17132144 |
| PMID | 40647441 |